vs
Cellectis S.A.（CLLS）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Cellectis S.A.的84.8倍（$805.5M vs $9.5M）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -265.9%，领先285.0%）。Cellectis S.A.同比增速更快（375.0% vs 28.3%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $27.6M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
CLLS vs NBIX — 直观对比
营收规模更大
NBIX
是对方的84.8倍
$9.5M
营收增速更快
CLLS
高出346.6%
28.3%
净利率更高
NBIX
高出285.0%
-265.9%
自由现金流更多
NBIX
多$358.4M
$27.6M
损益表 — Q2 2024 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $805.5M |
| 净利润 | $-25.3M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | -181.1% | 26.2% |
| 净利率 | -265.9% | 19.1% |
| 营收同比 | 375.0% | 28.3% |
| 净利润同比 | -51.9% | 49.1% |
| 每股收益（稀释后） | $-0.28 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSNBIX
| Q4 25 | — | $805.5M | ||
| Q3 25 | — | $794.9M | ||
| Q2 25 | — | $687.5M | ||
| Q1 25 | — | $572.6M | ||
| Q4 24 | — | $627.7M | ||
| Q3 24 | — | $622.1M | ||
| Q2 24 | $9.5M | $590.2M | ||
| Q1 24 | — | $515.3M |
净利润CLLSNBIX
| Q4 25 | — | $153.7M | ||
| Q3 25 | — | $209.5M | ||
| Q2 25 | — | $107.5M | ||
| Q1 25 | — | $7.9M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $129.8M | ||
| Q2 24 | $-25.3M | $65.0M | ||
| Q1 24 | — | $43.4M |
毛利率CLLSNBIX
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
营业利润率CLLSNBIX
| Q4 25 | — | 26.2% | ||
| Q3 25 | — | 30.1% | ||
| Q2 25 | — | 21.2% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | -181.1% | 24.6% | ||
| Q1 24 | — | 19.3% |
净利率CLLSNBIX
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 26.4% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | -265.9% | 11.0% | ||
| Q1 24 | — | 8.4% |
每股收益（稀释后）CLLSNBIX
| Q4 25 | — | $1.49 | ||
| Q3 25 | — | $2.04 | ||
| Q2 25 | — | $1.06 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | $-0.28 | $0.63 | ||
| Q1 24 | — | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $3.3B |
| 总资产 | $407.1M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSNBIX
| Q4 25 | — | $713.0M | ||
| Q3 25 | — | $340.2M | ||
| Q2 25 | — | $264.0M | ||
| Q1 25 | — | $194.1M | ||
| Q4 24 | — | $233.0M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | $149.0M | $139.7M | ||
| Q1 24 | — | $396.3M |
股东权益CLLSNBIX
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | $148.6M | $2.5B | ||
| Q1 24 | — | $2.4B |
总资产CLLSNBIX
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.3B | ||
| Q2 25 | — | $3.9B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | $407.1M | $3.3B | ||
| Q1 24 | — | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $386.0M |
| 自由现金流率自由现金流/营收 | 290.5% | 47.9% |
| 资本支出强度资本支出/营收 | 13.2% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | $743.9M |
8季度趋势，按日历期对齐
经营现金流CLLSNBIX
| Q4 25 | — | $388.4M | ||
| Q3 25 | — | $227.5M | ||
| Q2 25 | — | $102.0M | ||
| Q1 25 | — | $64.8M | ||
| Q4 24 | — | $242.5M | ||
| Q3 24 | — | $158.0M | ||
| Q2 24 | $28.9M | $64.6M | ||
| Q1 24 | — | $130.3M |
自由现金流CLLSNBIX
| Q4 25 | — | $386.0M | ||
| Q3 25 | — | $214.3M | ||
| Q2 25 | — | $89.5M | ||
| Q1 25 | — | $54.1M | ||
| Q4 24 | — | $235.2M | ||
| Q3 24 | — | $149.9M | ||
| Q2 24 | $27.6M | $53.0M | ||
| Q1 24 | — | $119.1M |
自由现金流率CLLSNBIX
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 27.0% | ||
| Q2 25 | — | 13.0% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | 290.5% | 9.0% | ||
| Q1 24 | — | 23.1% |
资本支出强度CLLSNBIX
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 13.2% | 2.0% | ||
| Q1 24 | — | 2.2% |
现金转化率CLLSNBIX
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
